{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:16:45Z","timestamp":1776356205459,"version":"3.51.2"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3324,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1038\/sj.mt.6300215","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T14:05:55Z","timestamp":1182261955000},"page":"1686-1693","source":"Crossref","is-referenced-by-count":233,"title":["Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow"],"prefix":"10.1016","volume":"15","author":[{"given":"Caroline J","family":"Breitbach","sequence":"first","affiliation":[]},{"given":"Jennifer M","family":"Paterson","sequence":"additional","affiliation":[]},{"given":"Chantal G","family":"Lemay","sequence":"additional","affiliation":[]},{"given":"Theresa J","family":"Falls","sequence":"additional","affiliation":[]},{"given":"Allison","family":"McGuire","sequence":"additional","affiliation":[]},{"given":"Kelley A","family":"Parato","sequence":"additional","affiliation":[]},{"given":"David F","family":"Stojdl","sequence":"additional","affiliation":[]},{"given":"Manijeh","family":"Daneshmand","sequence":"additional","affiliation":[]},{"given":"Kelly","family":"Speth","sequence":"additional","affiliation":[]},{"given":"David","family":"Kirn","sequence":"additional","affiliation":[]},{"given":"J Andrea","family":"McCart","sequence":"additional","affiliation":[]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[]},{"given":"John C","family":"Bell","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1038\/sj.mt.6300215_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/sj.mt.6300215_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1535-6108(03)00170-3","article-title":"Getting oncolytic virus therapies off the ground","volume":"4","author":"Bell","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1038\/sj.mt.6300215_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1359-6446(04)03221-0","article-title":"Oncolytic viruses for the treatment of cancer: current strategies and clinical trials","volume":"9","author":"Ries","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1038\/sj.mt.6300215_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/13543784.9.2.311","article-title":"Oncolytic viruses as novel anticancer agents: turning one scourge against another","volume":"9","author":"Smith","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1038\/sj.mt.6300215_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1038\/sj.mt.6300215_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymthe.2006.01.010","article-title":"Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells","volume":"14","author":"Bauerschmitz","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300215_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/10430340050015806","article-title":"Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney","volume":"11","author":"Ye","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1038\/sj.mt.6300215_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1089\/10430340050083289","article-title":"Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy","volume":"11","author":"Chen","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1038\/sj.mt.6300215_bib9","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1128\/JVI.74.10.4765-4775.2000","article-title":"Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant","volume":"74","author":"Ikeda","year":"2000","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300215_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ymthe.2004.08.015","article-title":"Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies","volume":"10","author":"Jiang","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300215_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2006.01.003","article-title":"Adenovirus type 5 interactions with human blood cells may compromise systemic delivery","volume":"14","author":"Lyons","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300215_bib12","first-page":"301","article-title":"Striking out at disseminated metastases: the systemic delivery of oncolytic viruses","volume":"8","author":"Fisher","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"10.1038\/sj.mt.6300215_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/sj.gt.3302736","article-title":"The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p)","volume":"13","author":"Shen","year":"2006","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300215_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bjc.1997.53","article-title":"The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion","volume":"75","author":"Parkins","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1038\/sj.mt.6300215_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/0008-5472.CAN-06-2871","article-title":"Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300215_bib16","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1038\/sj.mt.6300215_bib17","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/JVI.78.10.5368-5381.2004","article-title":"Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors","volume":"78","author":"Shayakhmetov","year":"2004","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300215_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/mthe.1999.0006","article-title":"Angiogenesis monitored by perfusion with a space-filling microbead suspension","volume":"1","author":"Springer","year":"2000","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300215_bib19","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1535-7163.MCT-05-0472","article-title":"Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery","volume":"5","author":"Martinive","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/sj.mt.6300215_bib20","first-page":"6371","article-title":"High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow","volume":"62","author":"Goertz","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300215_bib21","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300215_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","article-title":"The two NF-\u03baB activation pathways and their role in innate and adaptive immunity","volume":"25","author":"Bonizzi","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1038\/sj.mt.6300215_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nri1785","article-title":"Neutrophils and immunity: challenges and opportunities","volume":"6","author":"Nathan","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/sj.mt.6300215_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9255-2-4","article-title":"CXCR2 is critical for dsRNA-induced lung injury: relevance to viral lung infection","volume":"2","author":"Londhe","year":"2005","journal-title":"J Inflamm (Lond)"},{"key":"10.1038\/sj.mt.6300215_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/bmb\/ldh025","article-title":"Vascular ischaemia and reperfusion injury","volume":"70","author":"Eltzschig","year":"2004","journal-title":"Br Med Bull"},{"key":"10.1038\/sj.mt.6300215_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000179261","article-title":"Postischemic leukocyte\/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg","volume":"17","author":"Korthuis","year":"1997","journal-title":"Int J Microcirc Clin Exp"},{"key":"10.1038\/sj.mt.6300215_bib27","first-page":"H2653","article-title":"Effects of leukocyte capillary plugging in skeletal muscle ischemia-reperfusion injury","volume":"271","author":"Harris","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1038\/sj.mt.6300215_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1164\/rccm.2112012","article-title":"The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice","volume":"166","author":"Maus","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1038\/sj.mt.6300215_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/science.1636093","article-title":"An eosinophil-dependent mechanism for the antitumor effect of interleukin-4","volume":"257","author":"Tepper","year":"1992","journal-title":"Science"},{"key":"10.1038\/sj.mt.6300215_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood.V64.5.959.959","article-title":"Oxidants from phagocytes: agents of defense and destruction","volume":"64","author":"Babior","year":"1984","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300215_bib31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1172\/JCI112869","article-title":"Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins","volume":"79","author":"Henson","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1038\/sj.mt.6300215_bib32","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1172\/JCI112731","article-title":"\u03b11-Antitrypsin: molecular pathology, leukocytes, and tissue damage","volume":"78","author":"Carrell","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1038\/sj.mt.6300215_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/physrev.00023.2002","article-title":"Unique structural features that influence neutrophil emigration into the lung","volume":"83","author":"Burns","year":"2003","journal-title":"Physiol Rev"},{"key":"10.1038\/sj.mt.6300215_bib34","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1038\/sj.mt.6300215_bib35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/blood.V65.3.513.513","article-title":"Leukocyte-endothelial interactions","volume":"65","author":"Harlan","year":"1985","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300215_bib36","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.161.7.3631","article-title":"Inhibition of leukocyte emigration induced during the systemic inflammatory reaction in vivo is not due to IL-8","volume":"161","author":"Schleiffenbaum","year":"1998","journal-title":"J Immunol"},{"key":"10.1038\/sj.mt.6300215_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V79.1.152.152","article-title":"Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes","volume":"79","author":"Werfel","year":"1992","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300215_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/eji.200526175","article-title":"Solid tumors \u201cmelt\u201d from the inside after successful CD8 T cell attack","volume":"36","author":"Blohm","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1038\/sj.mt.6300215_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.cgt.7700819","article-title":"Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU\/leucovorin","volume":"12","author":"Reid","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/sj.mt.6300215_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.cgt.7700988","article-title":"Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver","volume":"14","author":"Au","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/sj.mt.6300215_bib41","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/sj.mt.6300215_bib42","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300215_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300215_bib44","first-page":"6463","article-title":"Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression","volume":"63","author":"Grote","year":"2003","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300215_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mt.6300039","article-title":"Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity","volume":"15","author":"Power","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300215_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0168-1702(01)00251-9","article-title":"Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells","volume":"76","author":"Desforges","year":"2001","journal-title":"Virus Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616320342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616320342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T04:11:02Z","timestamp":1707970262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616320342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1525001616320342"],"URL":"https:\/\/doi.org\/10.1038\/sj.mt.6300215","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}